Bevacizumab plus irinotecan stalls recurrent gliomas: Commentary
Publication
, Journal Article
Friedman, HS
Published in: Oncology Report
September 1, 2007
Duke Scholars
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
September 1, 2007
Issue
FALL
Start / End Page
9
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Friedman, H. S. (2007). Bevacizumab plus irinotecan stalls recurrent gliomas: Commentary. Oncology Report, (FALL), 9.
Friedman, H. S. “Bevacizumab plus irinotecan stalls recurrent gliomas: Commentary.” Oncology Report, no. FALL (September 1, 2007): 9.
Friedman HS. Bevacizumab plus irinotecan stalls recurrent gliomas: Commentary. Oncology Report. 2007 Sep 1;(FALL):9.
Friedman, H. S. “Bevacizumab plus irinotecan stalls recurrent gliomas: Commentary.” Oncology Report, no. FALL, Sept. 2007, p. 9.
Friedman HS. Bevacizumab plus irinotecan stalls recurrent gliomas: Commentary. Oncology Report. 2007 Sep 1;(FALL):9.
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
September 1, 2007
Issue
FALL
Start / End Page
9
Related Subject Headings
- Oncology & Carcinogenesis